GentleCure

What GentleCure does

GentleCure is a registered trademark and consumer-facing brand of SkinCure Oncology, LLC, a privately held company headquartered in Burr Ridge, Illinois. It delivers Image-Guided Superficial Radiation Therapy (IG-SRT), a surgery-free, FDA-cleared treatment for basal cell and squamous cell skin cancers (non-melanoma skin cancers). Treatment is administered across 18-25 outpatient sessions of approximately 10 minutes each, using the Sensus SRT-100 Vision device — the first and only skin cancer treatment platform that combines high-frequency ultrasound imaging with low-energy X-ray radiation to target lesions and track response over time.

The company's go-to-market operates through a dual-track model: direct-to-consumer marketing (website, social media, interactive treatment quiz, quarterly newsletter, and phone-based Skin Cancer Information Specialists) drives patient demand into a partner network of 345+ dermatology and Mohs surgery practices across the United States. SkinCure Oncology provides the technology platform, clinical training, administrative, and operational support to these practices, where certified Radiation Therapists deliver treatment. Revenue is generated on a per-treatment basis through Medicare and commercial insurance reimbursement, with clinical outcomes supported by a published Oncology Therapy journal study showing a 99.3% cure rate across 2,917 lesions in 1,632 patients, and 150,000+ patients treated cumulatively to date.

GentleCure was founded in 2015 alongside FDA clearance of the underlying device. The company is privately held with no disclosed venture capital or private equity investment, suggesting operational funding through profitable operations or strategic backing from SkinCure's parent structure. Active strategic priorities include defending Medicare and commercial insurance reimbursement through public advocacy, expanding the practice network across the United States, and substantiating outcomes through a longitudinal patient satisfaction survey program that has collected over 31,000 responses since April 2020.

Name

GentleCure

Legal name

SkinCure Oncology, LLC

Website

https://gentlecure.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

GentleCure, a brand of SkinCure Oncology, delivers Image-Guided Superficial Radiation Therapy — a surgery-free, FDA-cleared treatment for basal and squamous cell skin cancers — to patients through a network of 345+ dermatology practices nationwide.

Ownership category

akta.pro rank

Product category

Radiation Oncology / Skin Cancer Treatment Services

NAICS

Offices of Physicians (62111), Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Mohs Surgery & Skin Cancer (Dermatologic Oncology) (HLAKACAD), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

Keywords

• Skin cancer treatment
• Radiation therapy services
• Non-melanoma oncology
• Dermatology treatment services
• Superficial radiation therapy

Headquarters

HQ city

Illinois City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Image-Guided SRT Treatment Services: GentleCure (operated by SkinCure Oncology) generates revenue by providing the Image-Guided SRT treatment platform, technology, and operational support to dermatology practice partners. Treatment is billed per procedure/visit through Medicare and commercial insurance. Patients typically undergo 18-25 treatment sessions over several weeks.
2. Insurance Reimbursement: Medicare and most commercial insurance companies cover Image-Guided SRT treatment. Coverage depends on individual insurance plans. Treatment is performed in dermatology offices and billed through standard medical billing channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

GentleCure delivers Image-Guided Superficial Radiation Therapy (IG-SRT), a surgery-free treatment for basal cell and squamous cell skin cancers, using the Sensus SRT-100 Vision device to combine ultrasound imaging with low-energy X-ray radiation. Treatment is administered across 18–25 outpatient sessions in dermatology partner practices and is reimbursed primarily through Medicare and commercial insurance.

Product overview

GentleCure is a comprehensive surgery-free skin cancer treatment brand offering Image-Guided Superficial Radiation Therapy (IG-SRT). The core product is a medical treatment service delivered using the Sensus SRT-100 Vision device—the first and only skin cancer treatment platform with high-frequency ultrasound imaging. The treatment targets basal cell and squamous cell skin cancers with 99%+ cure rates across 18-25 outpatient sessions. The brand provides supporting resources including an online Treatment Quiz for candidacy assessment, Skin Cancer Information Specialists for patient support, a Patient Satisfaction Survey Program tracking outcomes since April 2020, and Patient Stories/Testimonials for education. The company partners with over 345 dermatology practices nationwide.

Differentiator

Problem solved

Functional benefit

Products and services

• GentleCure Image-Guided SRT Treatment Surgery-free, Image-Guided Superficial Radiation Therapy treatment for adults with basal cell or squamous cell skin cancer (including squamous cell carcinoma in-situ/Bowen's disease), delivered across 18–25 short outpatient sessions of about 10 minutes each in dermatology partner practices and reimbursed through Medicare and commercial insurance.
• Sensus SRT-100 Vision Platform (deployed via SkinCure Oncology) Proprietary medical device platform combining high-frequency ultrasound imaging with low-energy X-ray delivery, enabling dermatologists to see the exact size of a skin cancer, target a precise dose of X-ray energy, and visually track how the cancer shrinks over time during treatment.

Quantifiable outcome

• 99.3% cure rate for skin cancers treated (2,897 out of 2,917 skin cancers cured in clinical study of 1,632 patients)
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Dermatologists and Mohs Surgeons (Partner Practices)coreChannel Partner/ Reseller/ DistributorGentleCure / SkinCure Oncology partners with quality-focused dermatologists and Mohs surgeons across the United States. Partner practices receive the Image-Guided SRT platform (Sensus SRT-100 Vision device), along with clinical, administrative, and operational support. More than 345 practices participate nationwide. These practices deliver Image-Guided SRT treatment to patients in their offices, enabling patients to access surgery-free skin cancer treatment in community dermatology settings rather than hospitals or radiation centers.
• Sensus Healthcare (SRT-100 Vision Device)coreTechnology or IntegrationGentleCure / SkinCure Oncology uses the Sensus SRT-100 Vision device — the first and only skin cancer treatment platform with high-frequency ultrasound imaging — to deliver Image-Guided SRT. The technology enables precise ultrasound-guided targeting and treatment of basal and squamous cell skin cancers. This is a critical enabling technology partnership for the entire GentleCure treatment model.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cutera: Established medical aesthetics device company offering laser and energy-based systems widely used in dermatology practices. While not a direct skin cancer treatment competitor, it is a major incumbent device vendor in the same dermatology office channel and represents the kind of scaled dermatology-focused device company GentleCure's practice network buys from.
• Bausch Health Companies: Large diversified specialty pharmaceutical and medical device company with a significant dermatology franchise (Bausch + Lomb, Ortho Dermatologics). While broader than GentleCure's NMSC focus, it competes for dermatology practice relationships and offers prescription topical skin cancer therapies (e.g., Levulan) used as alternative NMSC treatments.

Emerging players

• DermTech: Non-invasive genomic skin diagnostic platform (DermTech Melanoma Test) operating in dermatology practices. Competes for share of voice on skin cancer diagnosis and treatment selection in the same dermatology channel that GentleCure targets, though focused on diagnostic decision-making rather than treatment delivery.
• MedX Health Corp: Developer of SIAscopy and DermSecure teledermatology platforms for skin lesion assessment and melanoma detection. Targets dermatology practices with non-invasive skin imaging, addressing adjacent workflow points (screening and triage) for the same NMSC patient population GentleCure treats.
• Castle Biosciences: Dermatology-focused molecular diagnostics company offering DecisionDx tests for skin cancers (including melanoma and cutaneous squamous cell carcinoma). Overlaps with GentleCure's clinical decision-making context for NMSC and is increasingly integrated into dermatology practice workflows, partially competing for the same dermatology partner mindshare.
• PhotoMedex (now part of Radiancy / Edge Systems): Provider of light-based and laser dermatology devices (historically XTRAC excimer laser for psoriasis/vitiligo) used in dermatology offices. Represents an alternative non-surgical, light/energy-based treatment modality that overlaps philosophically with GentleCure's surgery-free positioning in dermatology practices.

Direct peers

• Strata Skin Sciences: Commercial-stage dermatology device and services company providing in-office therapeutic and diagnostic systems, including solutions for non-melanoma skin cancer and psoriasis. Targets the same dermatology practice channel with recurring service-based economics, making it a directly comparable business model for non-surgical skin treatment.
• Sensus Healthcare: Manufactures the Sensus SRT-100 Vision device that powers every Image-Guided SRT treatment GentleCure delivers. Sensus is both the critical technology partner and a comparable skin cancer-focused radiation therapy company with its own superficial radiation therapy product line targeting the same dermatology channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GentleCureIGSRT
• YouTubeyoutube.com/@GentleCureIGSRT
• Facebookfacebook.com/GentleCureIGSRT
• Instagraminstagram.com/GentleCureIGSRT

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GentleCure